FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754487487> ?p ?o ?g. }

• W2754487487 abstract "Background Several studies have showed conflicting results regarding the presence and meaning of anti-phosphatidylserine/prothrombin (aPS/PT). However aPS/PT antibodies seem to be a risk factor for thrombosis. Nevertheless, most of the studies have focused on patients with SLE and secondary antiphospholipid syndrome (APS). Objectives To assess the prevalence of aPS/PT antibodies, as well as their association with other antiphospholipid (aPL) antibodies (specially lupus anticoagulant [LA]) and thrombosis, in a well-established cohort of primary APS from a single center. Methods We included 96 consecutive patients with primary APS according the Sydney classification criteria and/or patients with hematological features (thrombocytopenia and hemolytic anemia) attending a referral center in Mexico City. Patients from both groups fulfilled the Sydney laboratory criteria for APS. We registered demographics, disease duration and type of manifestation. aCL (IgG and IgM), antibodies to purified human anti-β2GP-I (IgG and IgM) and aPS/PT antibodies (IgG and IgM) were assessed by ELISA (INOVA Diagnostics). LA was determined by LA/1 screening reactant and a confirmatory test LA/2 according to published guidelines. We used chi-square (χ2) test, Spearman correlation analysis and logistic regression. Results Most patients were females (69.7%), mean age 44.5±14.6 and median disease duration 7.3 years. The main clinical features were thrombosis (n=74, 77%), hematologic involvement (n=49 patients, 51%) and obstetric events (n=24, 25%) (non-exclusive groups). The prevalence of LA was 69.8%, aCL-IgG 56.8%, anti-β2GP-l IgG 43.1%, aCL-IgM 31.5% and anti-β2GP-I IgM 21%. The frequency of aPS/PT antibodies was 61.2% and 61.6% for IgG and IgM isotype, respectively. When we compared patients with LA+ (n=58) vs. LA- (n=25), the first group had a higher prevalence of aPS/PT-IgG (79.3% vs.16%, p=0.0001) and aPS/PT-IgM antibody (81.5% vs. 31.8%, p=0.001), as well as higher titers (aPS/PT-IgG 130.5 U vs. 8.2 U and aPS/PT-IgM 58.5 U vs. 16.6 U, p=0.0001). aPS/PT-IgG antibodies correlated with aPS/PT-IgM (ρ=0.59, p=0.0001), aCL-IgG (ρ=0.62, p=0.0001), anti-β2GP-l IgG (ρ=0.63, p=0.001) and anti-β2GP-l IgM (ρ=0.35, p=0.001). On the other hand, aPS/PT IgM antibodies correlated with aCL-IgG (ρ=0.57, p=0.0001), aCL-IgM (ρ=0.42, p=0.001), anti-β2GP-l IgG (ρ=0.48, p=0.001) and anti-β2GP-l IgM (ρ =0.59, p=0.0001). We found moderate agreement between the presence of LA and both aPS/PT isotypes (k=0.58 p=0.0001 for IgG, and k=0.47 p=0.001 for IgM). Thrombosis was associated with aPS/PT-IgG antibodies (87.7% vs. 61.1%, p=0.003) but not with aPS/PT IgM (73.6% vs. 81.8%, p=0.37). At the logistic regression analysis, the aPS/PT IgG antibodies remained associated with thrombosis after adjusting by all other aPL antibodies, OR 8.6 95% CI 2.1–33.8, p=0.002. Conclusions In this cohort of patients with primary APS, aPS/PT antibodies were highly prevalent, correlated with other aPL antibodies and were associated independently with thrombosis. References Sciascia S, Sanna G, Marru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. Thrombosis Haemostasis 2014; 111:354–64. Disclosure of Interest None declared" @default.
• W2754487487 created "2017-09-25" @default.
• W2754487487 creator A5001699043 @default.
• W2754487487 creator A5004622179 @default.
• W2754487487 creator A5031924696 @default.
• W2754487487 creator A5032692436 @default.
• W2754487487 creator A5048004653 @default.
• W2754487487 creator A5057479863 @default.
• W2754487487 creator A5057775686 @default.
• W2754487487 date "2017-06-01" @default.
• W2754487487 modified "2023-10-18" @default.
• W2754487487 title "FRI0292 Anti-phosphatidylserine/prothrombin (APS/PT) antibodies in primary antiphospholipid syndrome" @default.
• W2754487487 doi "https://doi.org/10.1136/annrheumdis-2017-eular.5578" @default.
• W2754487487 hasPublicationYear "2017" @default.
• W2754487487 type Work @default.
• W2754487487 sameAs 2754487487 @default.
• W2754487487 citedByCount "0" @default.
• W2754487487 crossrefType "proceedings-article" @default.
• W2754487487 hasAuthorship W2754487487A5001699043 @default.
• W2754487487 hasAuthorship W2754487487A5004622179 @default.
• W2754487487 hasAuthorship W2754487487A5031924696 @default.
• W2754487487 hasAuthorship W2754487487A5032692436 @default.
• W2754487487 hasAuthorship W2754487487A5048004653 @default.
• W2754487487 hasAuthorship W2754487487A5057479863 @default.
• W2754487487 hasAuthorship W2754487487A5057775686 @default.
• W2754487487 hasBestOaLocation W27544874871 @default.
• W2754487487 hasConcept C126322002 @default.
• W2754487487 hasConcept C159654299 @default.
• W2754487487 hasConcept C203014093 @default.
• W2754487487 hasConcept C2776874634 @default.
• W2754487487 hasConcept C2780022809 @default.
• W2754487487 hasConcept C2780868729 @default.
• W2754487487 hasConcept C71924100 @default.
• W2754487487 hasConcept C72563966 @default.
• W2754487487 hasConcept C90924648 @default.
• W2754487487 hasConceptScore W2754487487C126322002 @default.
• W2754487487 hasConceptScore W2754487487C159654299 @default.
• W2754487487 hasConceptScore W2754487487C203014093 @default.
• W2754487487 hasConceptScore W2754487487C2776874634 @default.
• W2754487487 hasConceptScore W2754487487C2780022809 @default.
• W2754487487 hasConceptScore W2754487487C2780868729 @default.
• W2754487487 hasConceptScore W2754487487C71924100 @default.
• W2754487487 hasConceptScore W2754487487C72563966 @default.
• W2754487487 hasConceptScore W2754487487C90924648 @default.
• W2754487487 hasLocation W27544874871 @default.
• W2754487487 hasOpenAccess W2754487487 @default.
• W2754487487 hasPrimaryLocation W27544874871 @default.
• W2754487487 hasRelatedWork W1998907515 @default.
• W2754487487 hasRelatedWork W2018278396 @default.
• W2754487487 hasRelatedWork W2320439623 @default.
• W2754487487 hasRelatedWork W2411344449 @default.
• W2754487487 hasRelatedWork W2417069648 @default.
• W2754487487 hasRelatedWork W2553024926 @default.
• W2754487487 hasRelatedWork W2563349659 @default.
• W2754487487 hasRelatedWork W2611701585 @default.
• W2754487487 hasRelatedWork W2726871844 @default.
• W2754487487 hasRelatedWork W2751816785 @default.
• W2754487487 hasRelatedWork W2792928329 @default.
• W2754487487 hasRelatedWork W2799998004 @default.
• W2754487487 hasRelatedWork W2893843196 @default.
• W2754487487 hasRelatedWork W2907396361 @default.
• W2754487487 hasRelatedWork W2910721379 @default.
• W2754487487 hasRelatedWork W2921571112 @default.
• W2754487487 hasRelatedWork W2938775693 @default.
• W2754487487 hasRelatedWork W3029293740 @default.
• W2754487487 hasRelatedWork W3126967084 @default.
• W2754487487 hasRelatedWork W3178748373 @default.
• W2754487487 isParatext "false" @default.
• W2754487487 isRetracted "false" @default.
• W2754487487 magId "2754487487" @default.
• W2754487487 workType "article" @default.